EFPIA members' efforts against COVID-19: Merck

(2:5)

EFPIA members' efforts against COVID-19: a story from Pfizer Italy

(1:4)

EFPIA members' efforts against COVID-19: Janssen

(25)

EFPIA members' efforts against COVID-19: Farmindustria

(59)

ICH GUIDELINES

(11:25)

Regulatory Reliance Tools Unveiled: A Practical Guide by EMA

(1:31:21)

Workshop | A greener pharmaceutical supply chain for the people and planet

(2:25:54)

Countdown to the EU HTA: how can we seize this opportunity to improve patient access to medicines?

(1:27:37)

PFAS exposure, bioaccumulation and associations with health effects

(1:23:59)

Advancing the precision oncology agenda in the EU

(3:39:)

Innovative Approaches to Regulatory Reliance

(2:28)

EU JCA process: Opportunities and challenges in bringing innovative medicines to patients in Europe

(1:1:11)

Fireside Chat With Giacomo Chiesi, Head of Global Corporate Development, Chiesi Group #210

(13:53)

Pharma strategy: how to best improve access to innovative medicines? | POLITICO

(38:24)

EFPIA members' efforts against COVID-19: a story from Ipsen Italy

(1:35)

EFPIA members' efforts against COVID-19: Boehringer Ingelheim

(1:13)

EFPIA members' efforts against COVID-19: Pfizer Russia

(1:12)

EFPIA members' efforts against COVID-19: Lilly

(1:17)

EFPIA members' efforts against COVID-19: Boehringer Ingelheim

(1:5)

EFPIA members' efforts against COVID-19: Chiesi

(55)

EFPIA members' efforts against COVID-19: Pfizer UK

(1:4)

Working together for patients, with patients

(4:52)

Interview with Nathalie Moll, Director General, EFPIA

(5:20)

Why Europe must future-proof its pharma legislation

(2:16)

EFPIA members' efforts against COVID-19: Roche

(41)

Nathalie Moll, Director General, EFPIA

(1:2)

EFPIA WeWontRest

(1:8)